mTOR and AMPK Drive Preeclampsia — And Metformin May Help or Hurt
A new review maps how disrupted mTOR/AMPK signaling causes placental dysfunction in preeclampsia and evaluates metformin as a targeted therapy.
Summary
Preeclampsia is a dangerous pregnancy complication with no real treatment beyond delivery. This review examines how two key cellular energy sensors — mTOR and AMPK — become dysregulated during preeclampsia, impairing the placental cells that support fetal growth and triggering harmful blood vessel changes. In normal pregnancy, these two pathways work in balance. Under placental oxygen deprivation and oxidative stress, AMPK becomes overactive while mTOR is suppressed, damaging trophoblast function and flooding the bloodstream with anti-angiogenic factors. The review also scrutinizes metformin as a potential therapy, warning that while low-level AMPK activation may help restore balance, higher doses of metformin could deepen the very mTOR suppression driving the disease — a paradox demanding precise dosing strategies.
Detailed Summary
Preeclampsia affects roughly 2–8% of pregnancies worldwide and remains a leading cause of maternal and fetal death, with delivery of the placenta as the only definitive cure. Understanding the molecular drivers of this condition is critical for developing safer, targeted therapies — and this review argues that the mTOR/AMPK signaling axis sits at the center of its pathophysiology.
In a healthy pregnancy, mTORC1 and AMPK operate in coordinated opposition: mTORC1 promotes trophoblast growth and placental nutrient transport, while AMPK serves as an energy stress sensor. This balance enables adequate fetal nourishment and proper placental vascularization. The review systematically evaluates how chronic placental hypoxia and oxidative stress — hallmarks of preeclampsia — tip this balance destructively, causing excessive AMPK activation and suppressed mTORC1 signaling.
The consequences are significant. Dysfunctional trophoblast invasion leads to shallow placentation, and the resulting signaling cascade produces excess anti-angiogenic factors like sFlt-1 that drive the hypertension and end-organ damage characteristic of preeclampsia. The authors frame this axis as a unifying mechanistic explanation for diverse preeclampsia features.
Metformin, a widely used diabetes drug and longevity-associated compound that activates AMPK, emerges as a candidate therapy — but with an important caveat. The review highlights a dose-dependent paradox: while modest AMPK activation may restore metabolic equilibrium, higher doses or prolonged use could further suppress mTORC1, worsening the underlying imbalance. This finding calls for careful dose titration in any clinical application.
The review ultimately calls for placenta-directed therapeutic strategies and suggests that future trials of metformin in preeclampsia must account for this nuanced signaling interplay. For clinicians and researchers, this work offers a mechanistic framework for interpreting existing trial data and designing more precise interventions.
Key Findings
- Preeclampsia disrupts mTOR/AMPK balance, causing excess AMPK activity and reduced mTORC1, impairing trophoblast invasion.
- Dysfunctional trophoblasts overproduce anti-angiogenic factors like sFlt-1, driving hypertension and organ damage in preeclampsia.
- Low-dose AMPK activation may restore metabolic balance, but higher metformin doses risk deepening mTORC1 suppression.
- Placental hypoxia and oxidative stress are identified as the upstream triggers of mTOR/AMPK dysregulation in preeclampsia.
- Authors call for precisely titrated, placenta-directed therapies rather than systemic AMPK activation strategies.
Methodology
This is a narrative/systematic review synthesizing published literature on mTOR and AMPK signaling in preeclampsia and the pharmacology of metformin in this context. No original experimental or clinical data were generated by the authors. The scope covers mechanisms, pathophysiology, clinical features, and therapeutic implications.
Study Limitations
This summary is based on the abstract only, as the full paper was not accessible. The review appears to be a narrative or systematic synthesis without original data, limiting the strength of its clinical recommendations. The dose-response relationship between metformin and mTOR/AMPK signaling in pregnant women is not yet established in robust clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: